Regulatory 2024-11-07 | Quarterly Report Q3: Successful Outcome from Rights Issue with SEK 105 Million Extends Runway Until Late 2025 PDF Report Presentation Webcast
2024-11-06 | Ascelia Pharma Announces Completion of Full Study Report Reinforcing the Successful Outcomes of Orviglance Phase 3 Study SPARKLE PDF Report Presentation Webcast
Regulatory 2024-10-30 | Bulletin from the Extraordinary General Meeting in Ascelia Pharma AB on 30 October 2024 PDF Report Presentation Webcast
2024-10-24 | Ascelia Pharma Presents Late-Breaking Abstract on SPARKLE Data at the American Society of Nephrology Kidney Week Congress 2024 PDF Report Presentation Webcast
Regulatory 2024-10-04 | Notice of Extraordinary General Meeting in Ascelia Pharma AB PDF Report Presentation Webcast
Regulatory 2024-10-04 | Ascelia Pharma Announces Proposal for Election of Marianne Kock as New Member of the Board of Directors PDF Report Presentation Webcast
2024-10-01 | Ascelia Pharma Announces Acceptance of Orviglance SPARKLE Study Primary Results as Oral Presentation in Cutting-Edge Research at the 2024 RSNA Annual Meeting PDF Report Presentation Webcast
2024-09-30 | Ascelia Pharma Finalizes Rights Issue with Runway Extended to Late 2025 PDF Report Presentation Webcast
Regulatory 2024-09-30 | Change in Number of Shares and Votes in Ascelia Pharma AB PDF Report Presentation Webcast
Regulatory 2024-09-13 | Ascelia Pharma Resolves on a Directed Issue of Convertibles of SEK 7.5 Million PDF Report Presentation Webcast
Regulatory 2024-09-05 | Ascelia Pharma Announces Final Outcome in Fully Subscribed SEK 105 Million Rights Issue PDF Report Presentation Webcast
Regulatory 2024-09-04 | Ascelia Pharma Announces Preliminary Outcome in Rights Issue PDF Report Presentation Webcast
Regulatory 2024-08-16 | Ascelia Pharma Announces Prospectus in Connection with Rights Issue PDF Report Presentation Webcast
Regulatory 2024-08-15 | Half-Year Report 2024: Orviglance Completes Clinical Development with Successful Phase 3 Study PDF Report Presentation Webcast
Regulatory 2024-08-14 | Bulletin from the Extraordinary General Meeting in Ascelia Pharma AB on 14 August 2024 PDF Report Presentation Webcast
Regulatory 2024-08-09 | Ascelia Pharma Announces Final Terms of Rights Issue PDF Report Presentation Webcast
Regulatory 2024-07-10 | Notice of Extraordinary General Meeting in Ascelia Pharma AB PDF Report Presentation Webcast
Regulatory 2024-07-10 | Ascelia Pharma Carries Out a Rights Issue of Units of Approximately SEK 105 Million to Fully Finance the NDA Submission for Orviglance® PDF Report Presentation Webcast
